Immunotherapy drug improves outcomes in high-risk blood cancer
A Peter Mac-initiated clinical trial suggests a way to dramatically improve outcomes in patients with high-risk forms of large B-cell lymphoma, who otherwise have a 50% chance of cure from conventional therapy.
Patients enrolled... Read more